The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions

被引:20
作者
Aronson, Jeffrey K. [1 ]
Ferner, Robin E. [2 ,3 ]
机构
[1] Nuffield Dept Primary Care Hlth Sci, Ctr Evidence Based Med, Oxford OX2 6GG, England
[2] City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England
[3] Univ Birmingham, Sch Clin & Expt Med, Birmingham, W Midlands, England
关键词
dose-response relationship; drug-related adverse effects; drug-related adverse reactions; law of mass action; RISK; INDACATEROL; SAFETY;
D O I
10.1111/bcp.12706
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundAdverse drug reactions are sometimes described as being non-dose-related' because no relationship has been found between increasing doses and either the intensity of the response or the proportion of individuals in whom the response occurs; furthermore, hypersensitivity reactions are often regarded as being non-dose-related, even if different doses have not been studied. However, the law of mass action implies that all pharmacological effects are concentration related and should increase in intensity with increasing dose. We set out to explain this paradox. MethodsWe searched for published adverse drug reactions that have been described as non-dose-related and analysed them. ResultsWe identified four categories of explanations that resolve the paradox: (i) the reaction is not real; it may have occurred by chance or there may be methodological problems, such as bias or confounding factors; (ii) the dose-response curve for the adverse effect reaches a maximum at doses lower than were studied (i.e. a hypersusceptibility reaction); this underpins the use of test doses to predict the possibility of an adverse reaction at therapeutic doses; (iii) susceptibility to the adverse reaction differs widely among individuals; and (iv) imprecision or inaccuracy in the measurement of either dose or effect obscures dose responsiveness. This last explanation encompasses: (a) reactions related to cumulative dose; (b) dissociation between dose and concentration through saturable pharmacokinetics; and (c) variability in the measurement of the effect. Conclusions and implicationsIf an adverse drug reaction appears to be non-dose-related, the reasons should be sought, having these mechanisms in mind.
引用
收藏
页码:56 / 61
页数:6
相关论文
共 30 条
[1]   Preventability of Drug-Related Harms - Part II Proposed Criteria, Based on Frameworks that Classify Adverse Drug Reactions [J].
Aronson, Jeffrey K. ;
Ferner, Robin E. .
DRUG SAFETY, 2010, 33 (11) :995-1002
[2]   A Strategy for Regulatory Action When New Adverse Effects of a Licensed Product Emerge [J].
Aronson, Jeffrey K. ;
Price, Deirdre ;
Ferner, Robin E. .
DRUG SAFETY, 2009, 32 (02) :91-98
[3]   Clarification of terminology in drug safety [J].
Aronson, JK ;
Ferner, RE .
DRUG SAFETY, 2005, 28 (10) :851-870
[4]   The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview [J].
Calabrese, EJ ;
Blain, R .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2005, 202 (03) :289-301
[5]   THE LUPUS SYNDROME INDUCED BY HYDRALAZINE - A COMMON COMPLICATION WITH LOW-DOSE TREATMENT [J].
CAMERON, HA ;
RAMSAY, LE .
BRITISH MEDICAL JOURNAL, 1984, 289 (6442) :410-412
[6]  
CARSTAIRS KC, 1966, LANCET, V2, P133
[7]   An investigation of the laws of disinfection [J].
Chick, H .
JOURNAL OF HYGIENE, 1908, 8 (01) :92-158
[8]   Safety of indacaterol in the treatment of patients with COPD [J].
Donohue, James F. ;
Singh, Dave ;
Kornmann, Oliver ;
Lawrence, David ;
Lassen, Cheryl ;
Kramer, Benjamin .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2011, 6 :477-492
[9]   RISK-FACTORS FOR DEVELOPMENT OF FLUCLOXACILLIN ASSOCIATED JAUNDICE [J].
FAIRLEY, CK ;
MCNEIL, JJ ;
DESMOND, P ;
SMALLWOOD, R ;
YOUNG, H ;
FORBES, A ;
PURCELL, P ;
BOYD, I .
BRITISH MEDICAL JOURNAL, 1993, 306 (6872) :233-235
[10]   Interpreting atmospheric pollen counts for use in clinical allergy: allergic symptomology [J].
Frenz, DA .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2001, 86 (02) :150-157